April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
A Comparative Study of Latanoprost-Cationic Emulsion (Catioprost) and Latanoprost Aqueous Solution (Xalatan) in Preclinical Efficacy and Safety Models
Author Affiliations & Notes
  • Jean-Sebastien Garrigue
    R & D, Novagali Pharma, Evry, France
  • Grégory Lambert
    R & D, Septodont, St Maur des fosses, France
  • Laura Rabinovich
    R & D, Teva Pharmaceutics, Netanya, Israel
  • Philippe Daull
    R & D, Novagali Pharma, Evry, France
  • Janet B. Serle
    Ophthalmology, MSSM, New York, New York
  • Footnotes
    Commercial Relationships  Jean-Sebastien Garrigue, Novagali Pharma (E); Grégory Lambert, None; Laura Rabinovich, None; Philippe Daull, Novagali Pharma (E); Janet B. Serle, Aerie, Allergan, Lexicon, Novagali, PanOptica (F), Allergan, Altheos, (C), Merck, New World Medical (R)
  • Footnotes
    Support  NEI Core Grant EY001867 and an Unresticted grant from RPB
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 238. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jean-Sebastien Garrigue, Grégory Lambert, Laura Rabinovich, Philippe Daull, Janet B. Serle; A Comparative Study of Latanoprost-Cationic Emulsion (Catioprost) and Latanoprost Aqueous Solution (Xalatan) in Preclinical Efficacy and Safety Models. Invest. Ophthalmol. Vis. Sci. 2011;52(14):238.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The studies were designed to compare the ocular hypotensive effects, PK profiles, and ocular safety of the BAK-free latanoprost emulsion Catioprost® and the BAK-preserved latanoprost solution Xalatan® in cynomologus monkeys with glaucoma and rabbits, respectively.

Methods: : For the efficacy evaluation, glaucomatous eyes (high IOP was induced by laser photocoagulation of the trabecular meshwork) were instilled once a day for 5 consecutive days. Each monkey (n=8) received both test drugs, in a cross-over design with at least a 2-week washout period. IOP was measured at baseline, and at treatment days 1, 3, and 5; before drug instillation, then hourly for 6 hours. Latanoprost acid free ocular concentrations (cornea, conjunctiva, ciliary body, and aqueous humor) following a single instillation in rabbits were determined at time points 0.25, 0.5, 1, 4, 6, and 24h. The local tolerance of bid instillations for both formulations was assessed over a 28- day period in the rabbit (n=6 per group).

Results: : Both latanoprost formulations shared the same efficacy profile, and the IOP reduction lasted 24h. The maximum reduction in IOP occurred 2h after each morning dose and was 4.4±0.5 (-15%), 5.9±0.5 (-20%), and 7.8±0.8 mmHg (-26%) on treatment days 1, 3 and 5, respectively for Catioprost®. The same IOP reduction was observed for Xalatan®. This equivalence in efficacy was confirmed by the PK data. The comparison in AUCs demonstrated that the latanoprost-cationic emulsion was not significantly different from Xalatan®, 217 vs. 295 pg/mg.h in the ciliary body, respectively. While both formulations were well tolerated, the number of transient ocular reactions (conjunctiva redness) was reduced by 50% with the BAK-free Catioprost®. Neither ocular nor nasal mucosa histologic findings were noted for both formulations.

Conclusions: : The BAK-free latanoprost-cationic emulsion (Catioprost®) appears to be as potent as Xalatan® with an improved safety profile. Thus, Catioprost® may be a safer alternative to deliver therapeutic doses of latanoprost for the long term treatment of glaucoma.

Keywords: intraocular pressure • drug toxicity/drug effects • trabecular meshwork 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.